Bibliografisk note

Funding Information:
This work was supported by grants from the Ministry of Economy and Competitiveness, Instituto Carlos III (PI20/00392), CIBER Cardiovascular (16/11/00420 and 16/11/00403).

Funding Information:
: J.N. reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, Eli Lilly, Rovi, NovoNordisk, and Vifor Pharma (outside the submitted work). R.d.l.E. reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, and NovoNordisk (outside the submitted work). P.R. reports consulting for Bayer, CinCor, G3P, Idorsia, and KBP; honoraria from Ablative Solutions, AstraZeneca, Bayer, Boehringer Ingelheim, Corvidia, CVRx, Fresenius, Novartis, Novo Nordisk, Relypsa Inc., a Vifor Pharma Group Company, Roche, Sanofi, Sequana Medical, Servier, and Vifor Fresenius Medical Care Renal Pharma; Cofounder: CardioRenal, a company developing potassium and creatinine sensors for home monitoring. A.A.V. has received consultancy fees and/or research grants from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, Myokardia, Novartis, Novo Nordisk, and Roche Diagnostics. W.M. has received research grants from Novartis, Vifor, Medtronic, Biotronik, Abbott, and Boston Scientific. M.M. and O.C. report grants from Servier, Vifor and Novartis and other from Boehringer Ingelheim. J.L.J. is a Trustee of the American College of Cardiology, a board member of Imbria Pharmaceuticals, has received grant support from Applied Therapeutics, Innolife, Novartis Pharmaceuticals and Abbott Diagnostics, consulting income from Abbott, Janssen, Novartis, and Roche Diagnostics, and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, Bayer, CVRx, Janssen, MyoKardia and Takeda. C.M. has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the University Hospital Basel, the University of Basel, Abbott, Astra Zeneca, Beckman Coulter, Brahms, Idorsia, Novartis, LSI Medience Corporation, Ortho Clinical Diagnostics, Quidel, Roche, Siemens, Singulex, Sphingotec, all outside the current work, as well as speaker honoraria/consulting honoraria from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Idorsia, Novartis, Osler, Roche, Sanofi, and Singulex, all outside the current work and paid to the institution. A.M.R. reports research grants, advisory board fees and/or speakers honoraria/travel costs from AstraZeneca, NovoNordisk, Roche Diagnostics, Abbott Laboratories, Thermo Fisher, Critical Diagnostics, Novartis, Pfizer, Bayer, Medtronic, Boston Scientific, Sphingotec, and MiRXES. R.A.d.B. received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted the work). The UMCG, which employs Dr. de Boer has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., NovoNordisk, and Roche (outside the submitted work). S.D.A. reports receiving fees from Abbott, Actimed, Bayer, Boehringer Ingelheim, Cardiac Dimension, Cordio, Impulse Dynamics, Novartis, Occlutech, Servier, and Vifor Pharma, and grant support from Abbott and Vifor Pharma. A.C.S. received fees or grants from Bayer, Merck, AstraZeneca, Boehringer Ingelheim, Abbott, Novartis, We‐Health, Sanofi, and Vifor Pharma. M.B. is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TTR 219, project number 322900939) and reports personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, Servier and Vifor. E.A.J. reports grants and personal fees from Vifor Pharma, personal fees from Bayer, Novartis, Abbott, Boehringer Ingelheim, Pfizer, Servier, AstraZeneca, Berlin Chemie, Cardiac Dimensions, Respicardia, Takeda, Swixx Biopharma, Gedeon Richter, Radcliffe Group, Translational Medicine Academy, outside the submitted work. F.G. is an advisor to Pfizer, Ionis, Alnylam, Bayer, Pharmacosmos and Abbott; received speaker honoraria from Novartis, Orion Pharma, AstraZeneca, Vifor Pharma and Boehringer Ingelheim. P.S.J. employer the University of Glasgow has received payment from Novartis, AstraZeneca, NovoNordisk and Bayer for work on clinical trials, research support from Boehringer Ingelheim and Analog Devices Inc and speakers and advisory board fees from AstraZeneca, Novartis and Boehringer Ingelheim. L.H.L. reports grants, consulting fees and/or speaker's honoraria from Myocardia, AstraZeneca, Roche, Boehringer Ingelheim, Novartis, Bayer, Vifor, Sanofi, Servier, Abbott, Pharmacosmos, Medscape, Radcliffe, TMA, Orion Pharma, and stock ownership in AnaCardio, all outside the submitted work. B.M. reports personal fees and/or advisory board from AstraZeneca, Novartis, Boehringer Ingelheim, Eli‐Lilly, Servier, and Vifor Pharma. P.P. reports fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Corida, Cytokinetics, Impulse Dynamics, Novartis, Radcliffe, Servier, Vifor, all outside the current work. G.S. reports grants and personal fees from Vifor, AstraZeneca, grants from Boehringer Ingelheim, Novartis, Boston Scientific, Pharmacosmos, Merck, Bayer, personal fees from Società Prodotti Antibiotici, Roche, Servier, GENESIS, Cytokinetics, Medtronic, Teva, TMA, outside the submitted work. C.G.T. received funding from Amgen and personal fees from VivaLyfe, and is listed as an inventor on two heart failure patents. A.B.G. reports personal fees and/or advisory board from AstraZeneca, Novartis, Boehringer Ingelheim, Abbott, Roche Diagnostics, and Vifor Pharma. All other authors have nothing to disclose. Conflict of interest

Publisher Copyright:
© 2022 European Society of Cardiology.